Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586616 | 1.00 | NR1D1 (0.34) | NR1D1GPR119NR3C1PIK3CDKLKB1 | |
| SCHEMBL24176075 | 0.91 | GPR119 (0.35) | NR1D1GPR119NR3C1FAAH | |
| SCHEMBL26326435 | 0.84 | PARP1 (0.36) | NR1D1GPR119PIK3CDKLKB1PARP1 | |
| SCHEMBL24176212 | 0.75 | PARP1 (0.35) | NR1D1GPR119PARP1PARP2FAAH | |
| SCHEMBL26083470 | 0.72 | NPC1 (0.34) | — | |
| SCHEMBL26083478 | 0.72 | KLKB1 (0.32) | GPR119PIK3CDKLKB1 | |
| SCHEMBL26326436 | 0.72 | USP30 (0.37) | GPR119PIK3CDKLKB1 | |
| SCHEMBL26326387 | 0.72 | NPC1 (0.33) | PIK3CD | |
| SCHEMBL26326384 | 0.71 | NPC1 (0.33) | — | |
| SCHEMBL30368338 | 0.69 | MAPT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | NR1D1 3216/4885GPR119 3466/4885NR3C1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.